New pill shows promise for Hard-to-Treat cancers
NCT ID NCT03556228
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to check safety, find the best dose, and see if it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VMD-928 (a pill) and pembrolizumab (an immunotherapy drug)
- What this could lead to
- If successful, this could provide a new treatment option for people with certain advanced cancers that have stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not prove effective or may cause significant side effects. It is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atlantic Health System, Morristown Medical Center (site 124)
RECRUITINGMorristown, New Jersey, 07962, United States
-
Cancer Care Associates of York (site 206)
RECRUITINGYork, Pennsylvania, 17403, United States
-
Englewood Hospital and Medical Center (site 202)
RECRUITINGEnglewood, New Jersey, 07631, United States
-
Hartford Hospital (site 210)
RECRUITINGHartford, Connecticut, 06102, United States
-
Holy Cross Hospital (site 213)
RECRUITINGFort Lauderdale, Florida, 33308, United States
-
Memorial Cancer Institute at Memorial Healthcare Systems (site 132)
RECRUITINGPembroke Pines, Florida, 33028, United States
-
PanOncology Trials, Hospital Oncologico - Puerto Rico Medical Center, Río Piedras (site 200)
RECRUITINGSan Juan, 00935, Puerto Rico
-
Presbyterian Kaseman Hospital (site 208)
RECRUITINGAlbuquerque, New Mexico, 87110, United States
-
Providence Medical Foundation (site 209)
RECRUITINGSanta Rosa, California, 95403, United States
-
Summit Medical Group (site 205)
RECRUITINGFlorham Park, New Jersey, 07932, United States
-
Taylor Cancer Research Center (site 204)
RECRUITINGMaumee, Ohio, 43537, United States
-
The George Washington University Cancer Center (site 212)
RECRUITINGWashington D.C., District of Columbia, 20037, United States
-
The University of Texas MD Anderson Cancer Center (site 127)
RECRUITINGHouston, Texas, 77030, United States
-
Utah Cancer Specialists (site 203)
RECRUITINGSalt Lake City, Utah, 84106, United States
-
Weill Cornell Medicine, Cornell University (site 126)
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?